Biosimilars Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Significant Need for Affordable Access to High-Quality Biologic Treatments
   3. Market Restraints
      1. Intricate Development Process
      2. Patent Litigation and Regulatory Barriers
   4. Market Opportunities
      1. Surging Focus on Expanding the Therapeutic Scope of Biosimilars Beyond Conventional Biologics
   5. Market Trends
      1. Personalized Biosimilars
      2. E-prescribing Adoption
5. MARKET SEGMENTATION
   1. By Drug Class
      1. Monoclonal Antibodies
         1. Infliximab
         2. Trastuzumab
         3. Rituximab
         4. Adalimumab
         5. Other monoclonal antibodies
      2. Insulin
      3. Granulocyte Colony-Stimulating Factor
      4. Erythropoietin
      5. Recombinant Human Growth Hormone
      6. Etanercept
      7. Follitropin
      8. Teriparatide
      9. Interferons
      10. Anticoagulants
      11. Other Drug Class
   2. By Indication
      1. Oncology
      2. Inflammatory & Autoimmune Disorders
      3. Chronic Diseases
      4. Blood Disorders
      5. Growth Hormone Deficiency
      6. Infectious Diseases
      7. Other Indications
   3. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Amgen, Inc.
      2. Biocon Ltd
      3. Dr. Reddy’s Laboratories Ltd.
      4. Eli Lilly and Company
      5. Novartis AG
      6. Pfizer, Inc.
      7. Sandoz Group AG
      8. Teva Pharmaceuticals

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global biosimilars market?

The global market of biosimilars is projected to reach USD 122.75 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global biosimilarsmarket?

The global biosimilars market has an estimated annual growth rate of 15.5% .

Q.3. What are the recent trends of biosimilarsmarket?

Personalized biosimilars and E-prescribing adoptionare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in biosimilars?

The major companies profiled in this report include Amgen, Inc., Biocon Ltd, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Novartis AG, Pfizer, Inc., Sandoz Group AG, Teva Pharmaceuticals, among others.

Q.5. Which is the largest regional market in the Biosimilars?

North America is the largest regional market for Biosimilars.